A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

Inclusion Criteria:

• Was eligible for and has completed end of treatment visit of ALKS 2680 eligibleparent study in NT1, NT2 or IH. The current eligible studies are ALKS 2680-201 (Vibrance-1), ALKS 2680-202 (Vibrance-2) and ALKS 2680-203 (Vibrance-3)

• Is willing and able, and in the opinion of the treating physician can safelydiscontinue any medications prescribed for the management of narcolepsy symptoms, asapplicable, for 5 half-lives prior to Day 1 (for re-entry subjects), and for theduration of study (for all subjects)

Exclusion Criteria:

• Developed a new clinically significant health condition, ECG or laboratoryabnormality, in the opinion of the Investigator or Sponsor, may impact the subject'sparticipation in the study

• Is currently pregnant, breastfeeding, or planning to become pregnant during thestudy

• Is currently enrolled in another clinical study (other than the parent study) orused any investigational drug or device within 30 days prior to Screening